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A disintegrin and metalloprotease (ADAM) proteins are upregulated in cancer and can interact with
integrin receptors. We investigated whether such interactions may have functional signiﬁcance in
oral squamous cell carcinoma (OSCC).
ADAM 10 expression was increased in OSCC tissue and cell lines compared to normal oral mucosa.
Silencing of ADAM 10 reduced migration and invasion speciﬁcally in OSCC cells over-expressing
avb6 integrin. This may result from ADAM 10-induced up-regulation of MMPs.
We conclude ADAM 10 may inﬂuence OSCC invasion by functionally interacting with avb6 integrin
which we have previously shown is over expressed in OSCC.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
A disintegrin and metalloprotease (ADAM) are a family of trans-
membrane proteins which orchestrate interactions with the ECM
by proteolytically modifying cell surface proteins and acting as
adhesion molecules [1]. ADAM 10 is essential for normal develop-
ment and for differentiation of epithelial cells [2] largely through
Notch signalling [3]. ADAM 10 sheds numerous cell surface
proteins including TNFa [3] HB-EGF [4], TGFa [5] and EGF [6]
and is capable of mediating regulated intramembrane proteolysis
(RIP) of CD44 [7], cadherins [8], and notch [9], which leads to the
production of an intracellular fragment that can translocate to
the nucleus and inﬂuence gene transcription [10].
Despite advances in therapy the general prognosis of oral squa-
mous cell carcinoma (OSCC) remains poor, highlighting the need
for increased understanding of the molecular mechanisms
involved in disease progression. Over-expression of ADAM family
members has been reported in a range of malignancies [11–16]
including those of the oral cavity. ADAM 10 shows has proliferative
effects on OSCC cell lines [17] but the mechanism by which this
occurs is unclear.The pattern of expression of a number of integrins is changed in
cancer supporting the hypothesis that such molecules are inti-
mately involved in tumour progression [18]. The importance of
the integrin avb6 in OSCC has been widely reported [19,20].
Over-expression of this integrin and engagement to its ligand
ﬁbronectin on the surface of keratinocytes is thought to initiate a
pro-migratory cascade including up-regulation of MMP-2 and 9
[21,22].
Given that expression of ADAM 10 and integrin avb6 are altered
in OSCC and that interactions between integrins and ADAMs have
been shown to have functional signiﬁcance, we aimed to investi-
gate this further. We demonstrate that expression of ADAM 10 is
increased in OSCC and that reducing its expression by siRNA
modiﬁed cell motility speciﬁcally in cells over expressing the
avb6 integrin. Our data suggests one potential consequence of this
functional association is the modiﬁcation of MMP expression as a
result of engagement of avb6 with ADAM 10.2. Materials and methods
2.1. Patient samples
Tissue samples comprised 61 normal oral mucosa, 29 epithelial
dysplasias and 50 oral squamous cell carcinomas (25 cases with
and 25 without metastasis). Tissue micro-arrays were prepared
following examination of haematoxylin and eosin stained slides
and areas of interest marked using an objective marker (1.8 mm,
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ter and 3 mm in depth were harvested from each sampled area
using a manual tissue array (MTA-1 Mitogen, Beecher instruments
Inc.) and placed in a recipient parafﬁn block. For the OSCC cases,
cores were obtained from histologically normal mucosa, and from
the origin, body and advancing front of the tumour.
2.2. Immunohistochemistry
Sections were deparafﬁnised using xylene and ethanol and anti-
gen retrieval performed by microwaving for 8 min in Tris–EDTA
buffer.
Slides were washed in PBS and endogenous peroxide blocked
using 3% (v/v) H2O2 in methanol for 20 min. Non-speciﬁc blocking
was performed for 30 min with 100% (v/v) normal goat serum.
ADAM 10 antibody (Abcam; diluted 1:100 in goat serum) was ap-
plied to the sections and incubated overnight at 4 C. Secondary
anti-rabbit horseradish peroxidase-conjugated antibody, immun-
operoxidase kits and Vector NovaRed (VectorLabs), were used
according to manufacturer’s instructions. Slides were counter
stained with haematoxylin and mounted. Quantitative analysis
was performed using an Automated Cell Imaging System (ACIS
III, Dako). Initially, conventional microscopic analysis of approxi-
mately 10% of the cases was performed visually and scored accord-
ing to a modiﬁed Allred scoring system [23]. Threshold levels were
optimised within the ACIS III scoring system using the ‘learn by
example’ tool.
2.3. Cell culture and siRNA treatment
Three oral cancer cell lines [22] were selected with deﬁned inte-
grin expression patterns: H357 (negative for the av and b6 integrin
subunits), C1 (av positive, b6 negative) and VB6 (avb6 positive)
and cultured in keratinocyte growth medium as previously de-
scribed [24]. Integrin expression patterns for avb6 were conﬁrmed
by ﬂow cytometry [25] using monoclonal antibody MAB2077Z
(Millipore). Transfection of synthetic siRNA were performed as pre-
viously described [30], using oligofectamine (Life Technologies)
with ADAM 10 siRNA or a control siRNA (Life Technologies, ﬁnal
concentration 50 nM). Normal oral keratinocytes (NOK) were pre-
pared from outgrowth cultures of mucosal biopsies with appropri-
ate ethical approval.
2.4. mRNA and protein analysis
RNA was extracted using Trizol (Sigma–Aldrich) according to
the manufacturer’s instructions. Samples were treated with DNA-
ase I and cDNA generated using MultiScribe (Stratagene) reverse
transcriptase and qPCR performed using ADAM 10 and b2-micro-
globulin speciﬁc TaqMan gene expression assays (Applied Biosys-
tems). Protein extraction was performed with RIPA buffer (Sigma
Aldrich) containing protease inhibitors (Roche) and western blot
analysis performed as described previously [26]. Primary antibod-
ies for ADAM 10 (Calbiochem) and b-actin (Sigma–Aldrich) were
used at dilutions of 1:2000 and 1:5000 respectively. Blots were vis-
ualised using GeneSnap (Syngene) and densitometric analysis per-
formed by comparison with b-actin expression using Image J
(National Institute of Health, USA).
2.5. Adhesion assays
Ninety six well tissue culture plates (Corning) were coated
overnight at 4 C with either 10 lg/ml puriﬁed plasma ﬁbronectin
(Sigma–Aldrich) or PBS, then blocked with 1% (w/v) BSA for 1 h. 4
 104 cells were resuspended in serum free media and plated in
triplicate for 1 h at 37 C. Wells were washed, 100 ll of SFM with20 ll of MTS (Fisher Scientiﬁc, UK) added and absorbance read at
492 nm.
2.6. Migration assays
Migration chambers (8 lm pores, Corning) were coated for 1 h
at 37 C with either 10 lg/ml puriﬁed plasma ﬁbronectin or PBS
and blocked with migration buffer (3:1 of DMEM:F12 and 0.5%
(w/v) BSA) for 1 h. 1  105 cells were resuspended in 100 ll of
migration buffer, placed in the chambers and incubated at 37 C
for 4 h. Non-migrated cells were removed, samples ﬁxed in 10%
(v/v) buffered formalin, stained with haematoxylin and mounted
on glass slides. The number of migrated cells was determined by
counting ﬁve randomly selected ﬁelds.
2.7. Invasion assays
Matrigel coated invasion assays (BD Biosciences) were per-
formed using triplicate samples seeded at 3  105 cells/ml in low
serum media (3:1 of DMEM:F12 with 0.5% (v/v) FCS and 2% (w/v)
L-glutamine) in the inner chamber and KGM was used as a che-
mo-attractant. Plates were incubated for 16 h at 37 C and the in-
vaded cells processed and counted as above.
2.8. MMP assays
24 well culture plates were coated with 10 lg/ml of recombi-
nant ADAM 10 (R&D Systems), puriﬁed ﬁbronectin or PBS and
blocked with 0.1% (w/v) BSA at 37 C for 30 min. Serum-starved
cells were cultured until 90% conﬂuent. Media was removed, cells
washed and replaced with SFM for 24 h. Subsequently, the media
was removed, centrifuged and protein concentration determined
using a BCA assay (Thermo Scientiﬁc) and the number of adherent
cells counted using an automated cell counter (The Countess, Invit-
rogen). Electrophoresis using 10% (w/v) SDS–PAGE gels supple-
mented with 1 mg/ml of porcine gelatine was performed using
cell supernatants containing equal protein and MMP-2 and 9 stan-
dards (Millipore) diluted 1:400. Gels were re-natured in buffer
containing 2.5% (v/v) Triton X-100 and incubated overnight at
37 C in developing buffer as previously described [27]. Coomassie
Blue R-250 stained gels were scanned and analysed for MMP-2 and
9 activity by densitometry using Image J. MMP-2, 7 and 9 were
quantiﬁed by ELISA according to manufacturers’ instructions
(R&D Systems).
2.9. Statistical analysis
Kruskall Wallis and one way analysis of variance tests were per-
formed on cell-based and immunohistochemical data respectively,
using Analyse-It (Analyse-It Software Ltd., UK).
2.10. Ethics
Ethical approval for collection of primary normal oral keratino-
cytes (REC reference number: 04/Q2305/78) and for ADAM protein
immunohistochemistry on tissue sections (REC reference number:
07/H1309/105) was given by South Shefﬁeld Research Ethics
Committee.
3. Results
3.1. ADAM 10 is signiﬁcantly increased in OSCC compared to normal
oral mucosa and epithelial dysplasia
Most of the tissue cores examined demonstrated intense stain-
ing for ADAM 10, with the majority showing cytoplasmic staining
Fig. 2. Quantiﬁcation of ADAM 10 immunohistochemistry. Expression of ADAM 10
is signiﬁcantly increased (P < 0.0001) in the site of origin, main body and advancing
front of oral squamous cell carcinomas (n = 50) compared to normal oral mucosa
(n = 61) and epithelial dysplasia (n = 29).
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10 was signiﬁcantly increased (P < 0.0001) in all areas of oral squa-
mous cell carcinomas examined (41.2% ± 5.1, n = 50) compared to
normal oral mucosa (24.2% ± 4.1, n = 61) and dysplastic mucosa
(20.0% ± 6.5, n = 29, Fig. 2). Within the carcinomas, the highest
level of expression was found at the site of origin (47.4% ± 5.2,
n = 50) compared to the main body (43.9% ± 5.2) and advancing
front of the tumour (31.0% ± 4.4). ADAM 10 was signiﬁcantly
reduced in cases with metastatic disease compared to those
without metastasis and speciﬁc subsite analysis revealed
differences in expression at the advancing front (P = 0.003).
Histologically normal mucosa lying adjacent to tumour and in
cases of dysplasia with no evidence of malignancy showed
signiﬁcantly elevated ADAM 10 levels compared to normal oral
mucosa in patients without a history of cancer (Fig. 2; P = 0.004).
3.2. Oral cancer cell lines show increased expression of ADAM 10
compared to normal oral keratinocytes
Increased expression of ADAM 10 mRNA was found in all three
cancer cell lines compared to normal oral keratinocytes (P = 0.027,
Fig. 3a) and immunoblotting detected two bands at estimated Mw
of 105 and 60 kDa. NOKs showed similar levels of expression of the
105 kDa proform to the C1 cell line; however these were signiﬁ-
cantly lower (P = 0.020) than those seen in H357 and VB6 cells
(Fig. 3b). All cancer cell lines showedmarked elevation of the lower
molecular weight (60 kDa), corresponding to the molecular weightFig. 1. Haematoxylin and eosin staining and ADAM 10 immunohistochemistry. Represen
and (iii) oral squamous cell carcinoma are shown.reported for the catalytically active form of ADAM 10 [10], com-
pared to NOKs (P = 0.020).
3.3. ADAM 10 siRNA has no effect on adhesion of cancer cells to
ﬁbronectin
In accordance with our previous studies the b6 expressing cells
demonstrated a signiﬁcant increase in the level of adherence totative tissue samples from: (i) normal oral mucosa (ii) moderate epithelial dysplasia
Fig. 4. Migration and invasion of OSCC cell lines following RNAi knock down of
ADAM 10 expression. (a) The avb6 (VB6) over expressing cell line show a reduction
in migration to ﬁbronectin when treated with siRNA for ADAM 10 (mean ± S.E.,
⁄P = 0.007, DP = 0.001). (b) Both the null vector (C1) and avb6 (VB6) over expressing
cell lines show a reduction in invasion in ADAM 10 siRNA transfected cells
compared with controls (mean ± S.D., ⁄P < 0.001).
Fig. 3. Quantiﬁcation of ADAM 10 expression in oral cancer cell lines. (a) H357, C1
and VB6 cell lines show increased expression of ADAM 10 (⁄P = 0.027) assessed
using quantitative PCR when compared to NOKs. The raw CT values for expression
of ADAM 10 were 27.6 ± 0.2. (mean ± S.D., n = 3). (b) Western blot quantiﬁcation of
ADAM 10 protein expression; NOKS showed signiﬁcantly less of the ADAM 10
cleaved form (60 kDa) compared to oral cancer cell lines.
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qPCR conﬁrmed that siRNA-mediated depletion of ADAM 10 led
to a signiﬁcant reduction in transcript expression in all cell lines
tested (P < 0.001). However there were no signiﬁcant differences
in the level of attachment to ﬁbronectin between any of the cell
lines depleted of ADAM 10 and their respective controls (data
not shown).
3.4. Reduction of expression of ADAM 10 in avb6 over-expressing
(VB6) cells leads to decreased migration to ﬁbronectin
No difference in migration towards ﬁbronectin was found be-
tween untreated, control siRNA and mock transfected samples in
any cell line (Fig. 4a). H357 and C1 cells transfected with siRNA tar-
geted to ADAM 10 showed a slight increase in migratory capacity
to ﬁbronectin (119.8% ± 28.7 and 131.6 ± 24.8), whereas VB6 cells
showed a signiﬁcant reduction in migration (39.2 ± 8.5, P = 0.001,
Fig. 4a).
3.5. Decreased invasion is found following siRNA-mediated reduction
of ADAM 10 in avb6 over-expressing cells (VB6)
Variable effects were seen in each of the cell lines transfected
with ADAM 10 siRNA, no effect on invasion was observed forH357 (110.5% ± 2.9), while C1 and VB6 cells both showed a signif-
icant reduction in invasion relative to controls (68.4% ± 8.8 and
47.0 ± 1.9 respectively, P < 0.028). A signiﬁcantly greater reduction
in invasion following ADAM 10 depletion was seen in VB6 cells
compared with C1 cells (P < 0.001) (Fig. 4b).
3.6. Adhesion to ADAM 10 leads to altered MMP activity in av
expressing cells
The proform of MMP-2, with a predicted MW of 68 kDa, was
consistently identiﬁed by zymography in all treated samples with
activated forms seen at low levels (Fig. 5a). The C1 (4.7 ± 0.2 ng/ml)
and VB6 (5.5 ± 0.7 ng/ml) cells showed similar baseline levels of
MMP-2 production, but were signiﬁcantly elevated (P = 0.006)
compared to the H357 cells (1.3 ± 0.5 ng/ml, Fig. 5c). No effects
on MMP-2 expression were found when H357 and VB6 cells were
exposed to recombinant human ADAM 10 (rhADAM 10), but a sig-
niﬁcant down regulation was seen in C1 cells plated on rhADAM 10
(1.9 ± 0.4 ng/ml, P = 0.012). Compared to controls, cells plated on
rhADAM 10 showed marked differences in expression of MMP-7;
H357 cells showed little difference (0.9 ± 0.2 ng/ml) (P = 0.070),
C1 a reduction (0.3 ± 0.1 ng/ml, P = 0.006) and VB6 cells an in-
creased production (2.4 ± 0.1 ng/ml, P = 0.006, Fig. 5d). In VB6 cells,
rhADAM 10 stimulated a signiﬁcant increase in MMP-9
(8.4 ± 0.2 ng/ml, P = 0.010) compared to vehicle, but this was not
as large an increase as that produced in C1 cells (8.12 ± 0.75 ng/
ml, P = 0.006) which was nearly double the level of baseline
(Fig. 5b and e). There was however no signiﬁcant difference in
Fig. 5. Analysis of MMP expression following plating on recombinant ADAM 10. Representative zymography gels showing the proform of MMP-2 (a) and 9 (b) in H357 (i), C1
(ii) and VB6 (iii) cell lines. (c) ELISA analysis shows a reduction of MMP-2 in C1 cells plated on recombinant ADAM 10 (mean ± S.E.,⁄P = 0.012). (d) Oral cancer cell lines show
altered expression of MMP-7 when plated on recombinant ADAM 10 proteins (mean ± S.E., ⁄P = 0.048). C1 cells show a reduction in expression (0.3 ± 0.1 ng/ml), whereas VB6
cells showed signiﬁcantly increased production of MMP-7 (2.4 ± 0.1 ng/ml). (e) Oral cancer cell lines show altered expression patterns of MMP-9 when plated on recombinant
ADAM 10 (mean ± S.E., ⁄P = 0.048). VB6 cells show a slight increased production compared to baseline and show similar levels as cells plated on ﬁbronectin. C1 cells show a
marked increased production in MMP-9 compared to controls and produce similar levels to the VB6 cells (P = 0.006). H357 cells showed no detectable MMP-9 production in
any test condition.
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10.
4. Discussion
The observed increased expression of ADAM 10 in oral cancer
indicates that ADAM 10 may have important roles in the progres-
sion of invasion and is in agreement with other work [17]. The pre-
dominantly cytoplasmic expression of ADAM 10 was similar to
that previously noted in gastric cancer [12]. The heterogeneous
staining observed in our samples is similar to that seen in malig-
nant melanoma. However, expression in melanoma was increased
in cases with metastatic deposits but the reverse was true in our
cases [13].
All cancer cell lines analysed showed increased levels of ADAM
10 compared to normal oral keratinocytes, and we have shown
that ADAM 10, via its association with the integrin avb6, has func-
tional signiﬁcance in oral cancer and supports the role of ADAM 10
in migration and invasion [11,13]. Only the VB6 cells showed
reduced migration to ﬁbronectin on ADAM 10 depletion providing
evidence of a likely interaction between ADAM 10 and the integrin
avb6. The lack of effects on C1 and H357 cells indicate that the
effect on migration is unlikely to be a result of disruption of other
av integrin associations or non-speciﬁc integrin interactions.
Decreased levels of invasion in the av-expressing cells (C1 and
VB6) with little effect on the av negative cells (H357), suggests
an av-dependent process. Further reduction in invasion may berelated to the b6 domain. This work demonstrates the important
role of ADAM 10 in modulating the migratory behaviour of malig-
nant cells but the exact mechanisms of this are unknown. It may be
that this association inﬂuences ADAM 10 shedding, catalytic activ-
ity, integrin activity, or all of these.
A number of studies utilising clinical material have shown that
avb6 is an invasion related protein with expression being
increased in oral SCC [28] and salivary gland neoplasms [29].
Effective invasion does however appear to depend on the presence
locally of a suitable ligand such as Tenascin C, which could
promote downstream effects including modulation of MMP
expression. Our study suggests that ADAM 10 may also represent
a partner in this invasion inducing ‘molecular repertoire’ [29].
Ligand engagement by integrins is known to stimulate MMP
production in epithelial cells [30,31] and avb6 and MMP-9 levels
correlate in colon cancer and liver metastasis [32]. Stimulation of
C1 cells with ADAM 10 markedly raised MMP-9 levels to a similar
degree as that produced by the VB6 cells; this may be a mechanism
by which non-avb6 expressing OSCC may increase their invasive
capacity. The reasons for reduced production of MMP-2 in C1 cells
plated on recombinant ADAM 10 are unknown but it may be
related to a similar reduction in MMP-7, which is known to acti-
vate MMP-2. This reduction is not related to lack of adhesion to
ﬁbronectin as this led to increased production of MMP-9. Active
MMPs can be controlled by negative feedback [33] and it is
possible that ADAMs may also be involved in similar processes.
Production of MMP-7 was variable between each of the three cell
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the cells. Recombinant ADAM 10 had no effect on the levels of
MMP-7 secreted by H357 cells suggesting that this is av depen-
dent. The reduction of MMP-7 in the C1 cell lines may occur via
other b subunits that dimerise with the av subunits, whilst the in-
creased production in the VB6 line may be b6 dependent.
5. Conclusion
This work demonstrates a functional role for ADAM 10 in mod-
ulating the behaviour of malignant oral keratinocytes. It is likely
that this occurs via interaction with integrins and our data suggest
a speciﬁc interaction with integrin avb6. Both ADAMs and inte-
grins can stimulate the production of MMPs and therefore the like-
lihood of crosstalk between ADAMs, integrins and MMPs is a
potentially important mechanism by which cancer cells invade.
The use of selective ADAM inhibitors may be an important avenue
for future clinical management and recent studies appear to sup-
port this [34,35].
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